CLINICAL TRIALS PROFILE FOR CYMBALTA
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Cymbalta
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00105989 ↗ | Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder | Completed | Boehringer Ingelheim | Phase 3 | 2005-03-01 | The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder. |
| NCT00105989 ↗ | Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder | Completed | Eli Lilly and Company | Phase 3 | 2005-03-01 | The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder. |
| NCT00114127 ↗ | Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome | Completed | Massachusetts General Hospital | Phase 3 | 2004-06-01 | The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder. |
| NCT00177671 ↗ | Antidepressant Medication Plus Donepezil for Treating Late-life Depression | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2003-12-01 | This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression. |
| NCT00177671 ↗ | Antidepressant Medication Plus Donepezil for Treating Late-life Depression | Completed | University of Pittsburgh | Phase 4 | 2003-12-01 | This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression. |
| NCT00185575 ↗ | Duloxetine for the Treatment of Dysthymia | Completed | Eli Lilly and Company | N/A | 2004-09-01 | The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years. |
| NCT00185575 ↗ | Duloxetine for the Treatment of Dysthymia | Completed | Stanford University | N/A | 2004-09-01 | The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cymbalta
Condition Name
Clinical Trial Locations for Cymbalta
Trials by Country
Clinical Trial Progress for Cymbalta
Clinical Trial Phase
Clinical Trial Sponsors for Cymbalta
Sponsor Name
